Prospects of HA-based universal influenza vaccine

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Hashem, Anwar M ^a,b  

^a King Abdulaziz University   (Saudi Arabia)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; HEMAGGLUTININ; VIRUS ANTIBODY;

DRUG DELIVERY SYSTEM; DRUG IDENTIFICATION; HUMAN; INFLUENZA; NONHUMAN; REVIEW; VIRUS NEUTRALIZATION; ANIMAL; IMMUNOLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; HEMAGGLUTININS; HUMANS; INFLUENZA VACCINES;

EID: 84924308737     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/414637     Document Type: Review

References (143)

1. A. E. Fiore, D. K. Shay, K. Broder et al., "Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)," Morbidity and MortalityWeekly Report, vol. 58, pp. 1-52, 2009.
2. World Health Organization, "Influenza," Fact sheet no. 211, 2003.
3. S. Tong, Y. Li, P. Rivailler et al., "A distinct lineage of influenza A virus frombats," Proceedings of theNational Academy of Sciences of the United States of America, vol. 109, no. 11, pp. 4269-4274, 2012.
4. S. Tong, X. Zhu, Y. Li et al., "New world bats harbor diverse influenza a viruses," PLoS Pathogens, vol. 9, Article IDe1003657, 2013.
5. P. A. Rota, T. R.Wallis, M. W. Harmon, J. S. Rota, A. P. Kendal, and K. Nerome, "Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983," Virology, vol. 175, no. 1, pp. 59-68, 1990.
6. M. C. Zambon, "Epidemiology and pathogenesis of influenza," Journal of Antimicrobial Chemotherapy, vol. 44, pp. 3-9, 1999.
7. I. Capua and D. J. Alexander, "Human health implications of avian influenza viruses and paramyxoviruses," European Journal of Clinical Microbiology and Infectious Diseases, vol. 23, no. 1, pp. 1-6, 2004.
8. R. G. Webster, W. J. Bean, O. T. Gorman, T. M. Chambers, and Y. Kawaoka, "Evolution and ecology of influenza a viruses," Microbiological Reviews, vol. 56, no. 1, pp. 152-179, 1992.
9. P. Palese, "Influenza: old and new threats," Nature Medicine, vol. 10, pp. S82-S87, 2004.
10. S. Ludwig, L. Stitz, O. Planz, H. Van, W. M. Fitch, and C. Scholtissek, "European swine virus as a possible source for the next influenza pandemic?" Virology, vol. 212, no. 2, pp. 555-561, 1995.
11. K. M. Sturm-Ramirez, T. Ellis, B. Bousfield et al., "Reemerging H5N1 influenza viruses in Hong Kong in 2002 are highly pathogenic to ducks," Journal of Virology, vol. 78, no. 9, pp. 4892-4901, 2004.
12. A. C.-C. Shih, T.-C. Hsiao,M.-S. Ho, andW.-H. Li, "Simultaneous amino acid substitutions at antigenic sites drive influenza A hemagglutinin evolution," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 15, pp. 6283-6288, 2007.
13. D. A. Steinhauer and J. J. Skehel, "Genetics of influenza viruses," Annual Review of Genetics, vol. 36, pp. 305-332, 2002.
14. C. Scholtissek, W. Rohde, E. Harms, R. Rott, M. Orlich, and C. B. Boschek, "A possible partial heterozygote of an influenza a virus," Virology, vol. 89, no. 2, pp. 506-516, 1978.
15. Y. Kawaoka, S. Krauss, and R. G. Webster, "Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics," Journal of Virology, vol. 63, no. 11, pp. 4603-4608, 1968.
16. S. Ludwig, O. Planz, S. Pleschka, and T. Wolff, "Influenzavirus-induced signaling cascades: targets for antiviral therapy?" Trends in Molecular Medicine, vol. 9, no. 2, pp. 46-52, 2003.
17. R. B. Belshe, "Implications of the emergence of a novel H1 influenza virus,"The New England Journal ofMedicine, vol. 360, no. 25, pp. 2667-2668, 2009.
18. R. J. Garten, C. T. Davis, C. A. Russell et al., "Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans," Science, vol. 325, no. 5937, pp. 197-201, 2009.
19. K. Subbarao, A. Klimov, J. Katz et al., "Characterization of an avian influenza A (H5N1) virus isolated froma child with a fatal respiratory illness," Science, vol. 279, no. 5349, pp. 393-396, 1998.
20. Y. P. Lin, M. Shaw, V. Gregory et al., "Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 17, pp. 9654-9658, 2000.
21. R. A. M. Fouchier, P. M. Schneeberger, F. W. Rozendaal et al., "Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 5, pp. 1356-1361, 2004.
22. Centre for Disease Control and Prevention (CDC), CDC: Seasonal Influenza (Flu), 2014, http://www.cdc.gov/flu/avianflu/h7n9-virus.htm.
23. P. Palese, "Making better influenza virus vaccines?" Emerging Infectious Diseases, vol. 12, no. 1, pp. 61-65, 2006.
24. R. Bergen, S. Black, H. Shinefield et al., "Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents," Pediatric InfectiousDisease Journal, vol. 23,no. 2, pp. 138-144, 2004.
25. R. B. Belshe, K. L. Nichol, S. B. Black et al., "Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years," Clinical Infectious Diseases, vol. 39, no. 7, pp. 920-927, 2004.
26. US Food and Drug Administration (USFDA), "2012 Approval Letter-FluMist," http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm313179.htm.
27. European Center for Disease Prevention and Control (ECDC), http://www.ecdc.europa.eu/en/healthtopics/seasonal influenza/vaccines/Pages/influenza vaccination.aspx.
28. C. S. Ambrose and M. J. Levin, "The rationale for quadrivalent influenza vaccines," Human Vaccines & Immunotherapeutics, vol. 8, no. 1, pp. 81-88, 2012.
29. S. L. Epstein, "Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature,"TheJournal of Infectious Diseases, vol. 193, no. 1, pp. 49-53, 2006.
30. W. Gerhard, K. Mozdzanowska, and D. Zharikova, "Prospects for universal influenza virus vaccine," Emerging Infectious Diseases, vol. 12, no. 4, pp. 569-574, 2006.
31. R. B. Belshe, W. C. Gruber, P. M. Mendelman et al., "Correlates of immune protection induced by live, attenuated, coldadapted, trivalent, intranasal influenza virus vaccine," Journal of Infectious Diseases, vol. 181, no. 3, pp. 1133-1137, 2000.
32. C. S. Ambrose, M. J. Levin, and R. B. Belshe, "The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults," Influenza and other Respiratory Viruses, vol. 5, no. 2, pp. 67-75, 2011.
33. R. B. Belshe, P. M. Mendelman, J. Treanor et al., "The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children,"TheNew England Journal ofMedicine, vol. 338, no. 20, pp. 1405-1412, 1998.
34. J. M. Wood, "Selection of influenza vaccine strains and developing pandemic vaccines," Vaccine, vol. 20, supplement 5, pp. B40-B44, 2002.
35. F. Carrat and A. Flahault, "Influenza vaccine: the challenge of antigenic drift," Vaccine, vol. 25, pp. 6852-6862, 2007.
36. R. J. Drape, M. D. Macklin, L. J. Barr, S. Jones, J. R. Haynes, and H. J. Dean, "Epidermal DNA vaccine for influenza is immunogenic in humans," Vaccine, vol. 24, no. 21, pp. 4475-4481, 2006.
37. D. S. Fedson, "Pandemic influenza and the global vaccine supply," Clinical InfectiousDiseases, vol. 36,no. 12,pp. 1552-1561, 2003.
38. C. Buxton Bridges, W. W. Thompson, M. I. Meltzer et al., "Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial," The Journal of the AmericanMedical Association, vol. 284, no. 13, pp. 1655-1663, 2000.
39. M. de Filette, W. M. Jou, A. Birkett et al., "Universal influenza A vaccine: optimization of M2-based constructs," Virology, vol. 337, no. 1, pp. 149-161, 2005.
40. M. Aymard, M. Valette, B. Lina, and D. Thouvenot, "Surveillance and impact of influenza in Europe," Vaccine, vol. 17, supplement 1, pp. S30-S41, 1999.
41. A. Klimov, L. Simonsen, K. Fukuda, and N. Cox, "Surveillance and impact of influenza in the United States," Vaccine, vol. 17, supplement 1, pp. S42-S46, 1999.
42. J.C. de Jong, W. E. P. Beyer, A. M. Palache, G. F. Rimmelzwaan, and A. D. Osterhaus, "Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly," Journal of Medical Virology, vol. 61, no. 1, pp. 94-99, 2000.
43. K. Yohannes, P. Roche, A. Hampson, M. Miller, and J. Spencer, "Annual report of the National Influenza Surveillance Scheme, 2003," Communicable Diseases Intelligence, vol. 28, no. 2, pp. 160-168, 2004.
44. J. J. Skehel and D. C. Wiley, "Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin," Annual Review of Biochemistry, vol. 69, pp. 531-569, 2000.
45. K. J. Cross, W. A. Langley, R. J. Russell, J. J. Skehel, and D. A. Steinhauer, "Composition and functions of the influenza fusion peptide," Protein and Peptide Letters, vol. 16, no. 7, pp. 766-778, 2009.
46. R. G. Webster and W. G. Laver, "Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance," Virology, vol. 104, no. 1, pp. 139-148, 1980.
47. W. Gerhard, J. Yewdell, M. E. Frankel, and R. Webster, "Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies," Nature, vol. 290, no. 5808, pp. 713-717, 1981.
48. D. C. Wiley and J. J. Skehel, "The structure and function of the hemagglutinin membrane glycoprotein of influenza virus.," Annual Review of Biochemistry, vol. 56, pp. 365-394, 1987.
49. A. J. Caton, G. G. Brownlee, J. W. Yewdell, and W. Gerhard, "The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype)," Cell, vol. 31, no. 2, pp. 417-427, 1982.
50. D. C. Wiley, I. A. Wilson, and J. J. Skehel, "Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation," Nature, vol. 289, pp. 373-378, 1981.
51. J. Chen, S. A. Wharton, W. Weissenhorn et al., "A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pHinduced conformation," Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 26, pp. 12205-12209, 1995.
52. S. G. Lazarowitz and P. W. Choppin, "Enhancement of the infectivity of influenca A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide," Virology, vol. 68, no. 2, pp. 440-454, 1975.
53. T. Horimoto and Y. Kawaoka, "Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus," Journal of Virology, vol. 68, no. 5, pp. 3120-3128, 1994.
54. D. A. Steinhauer, "Role of hemagglutinin cleavage for the pathogenicity of influenza virus," Virology, vol. 258, no. 1, pp. 1-20, 1999.
55. S. Bertram, I. Glowacka, I. Steffen, A. Kühl, and S. Pöhlmann, "Novel insights into proteolytic cleavage of influenza virus hemagglutinin," Reviews in Medical Virology, vol. 20, no. 5, pp. 298-310, 2010.
56. M.-J. Gething, R. W. Doms, D. York, and J. White, "Studies on the mechanism of membrane fusion: site-specific mutagenesis of the hemagglutinin of influenza virus," The Journal of Cell Biology, vol. 102, no. 1, pp. 11-23, 1986.
57. G. J. Nabel and A. S. Fauci, "Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine," Nature Medicine, vol. 16, no. 12, pp. 1389-1391, 2010.
58. J. Steel, A. C. Lowen, T. T. Wang, M. Yondola, and Q. Gao, "Influenza virus vaccine based on the conserved hemagglutinin stalk domain," mBio, vol. 1, no. 1,Article ID e00018-10, 2010.
59. Y. Okuno, Y. Isegawa, F. Sasao, and S. Ueda, "A common neutralizing epitope conserved between the hemagglutinins of influenza A virusH1 and H2 strains," Journal of Virology, vol. 67, no. 5, pp. 2552-2558, 1993.
60. Y. A. Smirnov, A. S. Lipatov, A. K. Gitelman et al., "An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus," Acta Virologica, vol. 43,no. 4, pp. 237-244, 1999.
61. Y. A. Smirnov, A. S. Lipatov, A. K. Gitelman, E. C. J. Claas, and A. D. M. E. Osterhaus, "Prevention and treatment of bronchopneumonia in mice caused by mouse-adapted variant of avian H5N2 influenza A virus using monoclonal antibody against conserved epitope in the HA stem region," Archives of Virology, vol. 145, no. 8, pp. 1733-1741, 2000.
62. S. Sakabe, K. Iwatsuki-Horimoto, T. Horimoto et al., "A crossreactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection," Antiviral Research, vol. 88, no. 3, pp. 249-255, 2010.
63. C. Dreyfus, D. C. Ekiert, and I. A. Wilson, "Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin," Journal of Virology, vol. 87, no. 12, pp. 7149-7154, 2013.
64. J. Sui, W. C. Hwang, S. Perez et al., "Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses," Nature Structural&Molecular Biology, vol. 16, no. 3, pp. 265-273, 2009.
65. M. Throsby, E. van den Brink, M. Jongeneelen et al., "Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells," PLoS ONE, vol. 3, no. 12, Article IDe3942, 2008.
66. D. C. Ekiert, G. Bhabha, M.-A. Elsliger et al., "Antibody recognition of a highly conserved influenza virus epitope," Science, vol. 324, no. 5924, pp. 246-251, 2009.
67. D. C. Ekiert, A. K. Kashyap, J. Steel et al., "Cross-neutralization of influenza a viruses mediated by a single antibody loop," Nature, vol. 489, no. 7417, pp. 526-532, 2012.
68. D. Corti, A. L. Suguitan Jr., D. Pinna et al., "Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine," The Journal of Clinical Investigation, vol. 120, no. 5, pp. 1663-1673, 2010.
69. R. Burioni, F. Canducci,N.Mancini et al., "Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV)," New Microbiologica, vol. 32, no. 4, pp. 319-324, 2009.
70. R. Burioni, F. Canducci, N. Mancini et al., "Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV)," Virology, vol. 399, no. 1, pp. 144-152, 2010.
71. D. de Marco, N. Clementi, N. Mancini et al., "A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses," PLoS ONE, vol. 7, no. 4, Article ID e34415, 2012.
72. J.Wrammert, D. Koutsonanos, G. M. Li et al., "Broadly crossreactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection," Journal of Experimental Medicine, vol. 208, no. 1, pp. 181-193, 2011.
73. A. K.Kashyap, J. Steel, A. F. Oner et al., "Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 16, pp. 5986-5991, 2008.
74. A. K. Kashyap, J. Steel, A. Rubrum et al., "Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries," PLoS Pathogens, vol. 6, no. 7, Article ID e1000990, 7 pages, 2010.
75. G.-M. Li, C. Chiu, J. Wrammert et al., "Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 23, pp. 9047-9052, 2012.
76. D. C. Ekiert, R. H. E. Friesen, G. Bhabha et al., "A highly conserved neutralizing epitope on group 2 influenza A viruses," Science, vol. 333, no. 6044, pp. 843-850, 2011.
77. R. H. Friesen, P. S. Lee, E. J. Stoop et al., "A common solution to group 2 influenza virus neutralization," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 1, pp. 445-450, 2014.
78. D. Corti, J. Voss, S. J. Gamblin et al., "A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins," Science, vol. 333, no. 6044, pp. 850-856, 2011.
79. N. Clementi, D. de Marco, N. Mancini et al., "A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes," PLoS ONE, vol. 6, no. 12, Article ID e28001, 2011.
80. G. Nakamura, N. Chai, S. Park et al., "An in vivo humanplasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies," Cell Host andMicrobe, vol. 14, no. 1, pp. 93-103, 2013.
81. C. Dreyfus, N. S. Laursen, T. Kwaks et al., "Highly conserved protective epitopes on influenza B viruses," Science, vol. 337, no. 6100, pp. 1343-1348, 2012.
82. X. Yu, T. Tsibane, P. A. McGraw et al., "Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors," Nature, vol. 455, no. 7212, pp. 532-536, 2008.
83. T. Tsibane, D. C. Ekiert, J. C. Krause et al., "Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity inH1N1 viruses," PLoS Pathogens, vol. 8, no. 12, Article ID e1003067, 2012.
84. J. C. Krause, D. C. Ekiert, T. M. Tumpey, P. B. Smith, I. A. Wilson, and J. E. Crowe, "An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody," mBio, vol. 2, no. 1, 2011.
85. J. C. Krause, T. Tsibane, T. M. Tumpey, C. J. Huffman, C. F. Basler, and J. E. Crowe Jr., "A broadly neutralizing humanmonoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin," Journal of Virology, vol. 85, no. 20, pp. 10905-10908, 2011.
86. R.Xu, D. C. Ekiert, J.C.Krause, R. Hai, J. E. Crowe Jr., and I. A. Wilson, "Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus," Science, vol. 328, no. 5976, pp. 357-360, 2010.
87. M. Hong, P. S. Lee, R. M. B. Hoffman et al., "Antibody recognition of the pandemic H1N1 influenza virus hemagglutinin receptor binding site," Journal of Virology, vol. 87, no. 22, pp. 12471-12480, 2013.
88. J. R. R. Whittle, R. Zhang, S. Khurana et al., "Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 34, pp. 14216-14221, 2011.
89. A. G. Schmidt, H. Xu, A. R. Khan et al., "Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 1, pp. 264-269, 2013.
90. J. C. Krause, T. Tsibane, T. M. Tumpey et al., "Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses," Journal of Virology, vol. 86, no. 11, pp. 6334-6340, 2012.
91. R. Xu, J. C. Krause, R. Mcbride, J. C. Paulson, J. E. Crowe Jr., and I. A. Wilson, "A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin," Nature Structural and Molecular Biology, vol. 20, no. 3, pp. 363-370, 2013.
92. T. Shibuya, T. Yamashiro, Y. Masaike, M. Ohuchi, G.-I. Uechi, and A. Nishizono, "Identification of a human monoclonal Fab with neutralizing activity against H3N2 influenza A strain from a newly constructed human Fab library," Microbiology & Immunology, vol. 52, no. 3, pp. 162-170, 2008.
93. N. Ohshima, Y. Iba, R. Kubota-Koketsu, Y. Asano, Y. Okuno, and Y. Kurosawa, "Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5," Journal of Virology, vol. 85, no. 21, pp. 11048-11057, 2011.
94. Y. Iba, Y. Fujii, N. Ohshima et al., "Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses," Journal of Virology, vol. 88, no. 13, pp. 7130-7144, 2014.
95. L. Sun, X. Lu, C. Li et al., "Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses," PLoS ONE, vol. 4, no. 5,Article ID e5476, 2009.
96. C. P. Simmons, N. L. Bernasconi, A. L. Suguitan Jr. et al., "Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza," PLoS Medicine, vol. 4, no. 5, article e178, 2007.
97. S. Khurana, A. L. Suguitan Jr., Y. Rivera et al., "Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets," PLoS Medicine, vol. 6, no. 4, Article ID e1000049, 2009.
98. R. Yoshida, M. Igarashi, H. Ozaki et al., "Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses," PLoS Pathogens, vol. 5, no. 3,Article ID e1000350, 2009.
99. P. S. Lee, R. Yoshida, D. C. Ekiert et al., "Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 42, pp. 17040-17045, 2012.
100. D. J. DiLillo, G. S. Tan, P. Palese, and J. V. Ravetch, "Broadly neutralizing hemagglutinin stalk-specific antibodies require FcR interactions for protection against influenza virus in vivo," Nature Medicine, vol. 20, pp. 143-151, 2014.
101. N. Pica, R. Hai, F. Krammer et al., "Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 7, pp. 2573-2578, 2012.
102. C. A.Thomson, Y.Wang, L. M. Jackson et al., "Pandemic H1N1 influenza infection and vaccination in humans induces crossprotective antibodies that target the hemagglutinin stem," Frontiers in Immunology, vol. 3, article 87, 2012.
103. M. S. Miller, T. Tsibane, F. Krammer et al., "1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans," Journal of Infectious Diseases, vol. 207, no. 1, pp. 98-105, 2013.
104. X.-S. He, S. Sasaki, J. Baer et al., "Heterovariant cross-reactive B-cell responses induced by the 2009 pandemic influenza virus A subtype H1N1 vaccine," The Journal of Infectious Diseases, vol. 207, no. 2, pp. 288-296, 2013.
105. B.-Z. Wang, R. Xu, F.-S. Quan, S.-M. Kang, L. Wang, and R. W. Compans, "Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection," PLoS ONE, vol. 5, no. 11, Article ID e13972, 2010.
106. J. V. Pérez-Girón, A. Belicha-Villanueva, E. Hassan et al., "Mucosal polyinosinic-polycytidylic acid improves protection elicited by replicating influenza vaccines via enhanced dendritic cell function and T cell immunity," The Journal of Immunology, vol. 193, no. 3, pp. 1324-1332, 2014.
107. Y.-N. Lee, M.-C. Kim, Y.-T. Lee et al., "AS04-adjuvanted viruslike particles containing multiple M2 extracellular domains of influenza virus confer improved protection," Vaccine, vol. 32, no. 35, pp. 4578-4585, 2014.
108. N. Budimir, A. de Haan, T. Meijerhof et al., "Critical role of TLR7 signaling in the priming of cross-protective cytotoxic T lymphocyte responses by a whole inactivated influenza virus vaccine," PLoS ONE, vol. 8, no. 5,Article ID e63163, 2013.
109. P. H. Goff, D. Eggink, C.W. Seibert et al., "Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies," PLoS ONE, vol. 8, no. 11, Article ID e79194, 2013.
110. T. Nolan, L. Bravo, A. Ceballos et al., "Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children," Vaccine, vol. 32, pp. 6146-6156, 2014.
111. Z. Staneková, I. Adkins, M. Kosová, J. Janulíková, P. Sebo, and E. Varecková, "Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin," Antiviral Research, vol. 97, no. 1, pp. 24-35, 2013.
112. X. Fan, A. M. Hashem, Z. Chen et al., "Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes," Mucosal Immunology, vol. 8, pp. 211-220, 2015.
113. T. Lambe, "Novel viral vectored vaccines for the prevention of influenza,"MolecularMedicine, vol. 18,no. 8, pp. 1153-1160, 2012.
114. E.A.Weaver, A.M. Rubrum,R. J.Webby, andM. A. Barry, "Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin," PLoS ONE, vol. 6, no. 3, Article ID e18314, 2011.
115. J. Yan, D. O. Villarreal, T. Racine et al., "Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine," Vaccine, vol. 32, no. 24, pp. 2833-2842, 2014.
116. M.-W. Chen, T.-J. R. Cheng, Y. Huang et al., "A consensushemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 36, pp. 13538-13543, 2008.
117. A. Schneemann, J. A. Speir, G. S. Tan et al., "A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin," Journal of Virology, vol. 86, no. 21, pp. 11686-11697, 2012.
118. A. Morokutti, T. Muster, and B. Ferko, "Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans," Vaccine, vol. 32, no. 17, pp. 1897-1900, 2014.
119. F.-S. Quan, R.W. Compans, and S.-M. Kang, "Oral vaccination with inactivated influenza vaccine induces cross-protective immunity," Vaccine, vol. 30, no. 2, pp. 180-188, 2012.
120. C. J. Wei, J. C. Boyington, P. M. McTamney et al., "Induction of broadly neutralizingH1N1 influenza antibodies by vaccination," Science, vol. 329, no. 5995, pp. 1060-1064, 2010.
121. T. T. Wang, G. S. Tan, R. Hai et al., "Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 44, pp. 18979-18984, 2010.
122. S. Chun, C. Li, G. van Domselaar et al., "Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins," Vaccine, vol. 26, no. 48, pp. 6068-6076, 2008.
123. C. Li, B. Jaentschke, Y. Song et al., "A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide," Nature Protocols, vol. 5, no. 1, pp. 14-19, 2010.
124. A. M. Hashem, G. van Domselaar, C. Li et al., "Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus," Biochemical and Biophysical Research Communications, vol. 403, no. 2, pp. 247-251, 2010.
125. C. Gravel, C. Li, J. Wang et al., "Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays," Journal of Visualized Experiments, vol. 4, no. 50, article 2784, 2011.
126. N. Prabhu, M. Prabakaran, H.-T. Ho et al., "Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection," Journal of Virology, vol. 83, no. 6, pp. 2553-2562, 2009.
127. W. Hu, A. Chen, Y. Miao et al., "Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient," Virology, vol. 435, no. 2, pp. 320-328, 2013.
128. E. Tsuchiya, K. Sugawara, S.Hongo et al., "Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus," Journal of General Virology, vol. 82, no. 10, pp. 2475-2484, 2001.
129. S. E. Hensley, S. R. Das, A. L. Bailey et al., "Hemagglutinin receptor binding avidity drives influenza a virus antigenic drift," Science, vol. 326, no. 5953, pp. 734-736, 2009.
130. H. Sagawa, A. Ohshima, I. Kato, Y. Okuno, and Y. Isegawa, "The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region," Journal of General Virology, vol. 77, no. 7, pp. 1483-1487, 1996.
131. K. Uranowska, J. Tyborowska, A. Jurek, B. Szewczyk, and B. Gromadzka, "Hemagglutinin stalk domain fromH5N1 strain as a potentially universal antigen," Acta Biochimica Polonica, vol. 61, no. 3, pp. 541-550, 2014.
132. G. Bommakanti, M. P. Citron, R. W. Hepler et al., "Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 31, pp. 13701-13706, 2010.
133. D. Eggink, P. H. Goff, and P. Palese, "Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain," Journal of Virology, vol. 88, no. 1, pp. 699-704, 2014.
134. S.-C. Lin,W.-C. Liu, J.-T. Jan, and S.-C.Wu, "Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses," PLoS ONE, vol. 9, no. 3, Article ID e92822, 2014.
135. I. Margine, F. Krammer, R. Hai et al., "Hemagglutinin stalkbased universal vaccine constructs protect against group 2 influenza A viruses," Journal of Virology, vol. 87, no. 19, pp. 10435-10446, 2013.
136. F. Krammer, N. Pica, R. Hai, I. Margine, and P. Palesea, "Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies," Journal of Virology, vol. 87, no. 12, pp. 6542-6550, 2013.
137. F. Krammer, R. Hai, M. Yondola et al., "Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets," Journal of Virology, vol. 88, no. 6, pp. 3432-3442, 2014.
138. P. Yang, Y. Duan, P. Zhang et al., "Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination," PLoS ONE, vol. 7, no. 1,Article ID e30252, 2012.
139. S. Rao, W.-P. Kong, C.-J. Wei et al., "Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice," PLoS ONE, vol. 3, no. 6, Article ID e2432, 2008.
140. F. Zhou, G. Wang, P. Buchy et al., "A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses," Journal of Virology, vol. 86, no. 12, pp. 6970-6978, 2012.
141. S. Wang, A. Hackett, N. Jia et al., "Polyvalent DNA vaccines expressing HA antigens of H5N1 influenza viruses with an optimized leader sequence elicit cross-protective antibody responses," PLoS ONE, vol. 6, no. 12, Article ID e28757, 2011.
142. S. V. Vemula, Y. S. Ahi, A. M. Swaim et al., "Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness," PLoS ONE, vol. 8, no. 4,Article ID e62496, 2013.
143. M. Prabakaran, S. Leyrer, F. He et al., "Progress toward a universal H5N1 vaccine: a recombinant modified vaccinia virusAnkara-expressing trivalent hemagglutinin vaccine," PLoS ONE, vol. 9, no. 9,Article ID e107316, 2014.